Search results

Filter (6 in use)

Type 4 selected

  • Remove filter for NICE advice (3)
  • Remove filter for NICE Pathways
  • Remove filter for Local practice
  • Remove filter for News

Last updated 1 selected

  • Filter by Last 3 months
  • Filter by Last 6 months
  • Remove filter for Last year
  • Filter by Last 3 years

Advice programme 1 selected

  • Filter by Medtech innovation briefings (40)
  • Filter by Evidence summaries (11)
  • Filter by COVID-19 rapid summaries (7)
  • Remove filter for Antimicrobial prescribing (3)

3 results

Sorted by Relevance . | Sort by Date

  • NICE advice Remove NICE advice filter
  • NICE Pathways Remove NICE Pathways filter
  • Local practice Remove Local practice filter
  • News Remove News filter
  • Last year Remove Last year filter
  • Antimicrobial prescribing Remove Antimicrobial prescribing filter
  1. Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)

    Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam

    Type
    Evidence summary: antimicrobial prescribing
    Published
    28 October 2020
  2. Antimicrobial prescribing: cefiderocol (ES31)

    Summary of the evidence on antimicrobial prescribing: cefiderocol

    Type
    Evidence summary: antimicrobial prescribing
    Published
    02 December 2020
  3. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Type
    Evidence summary: antimicrobial prescribing
    Published
    05 January 2021